A5012623658- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Cytomegalovirus and herpesvirus research
- Herpesvirus Infections and Treatments
- Endometriosis Research and Treatment
- T-cell and Retrovirus Studies
- Immune Cell Function and Interaction
- Linguistic research and analysis
- Uterine Myomas and Treatments
- Delphi Technique in Research
- Viral-associated cancers and disorders
- Virus-based gene therapy research
- Pregnancy-related medical research
- Polyomavirus and related diseases
- Hepatitis C virus research
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV-related health complications and treatments
- Animal Disease Management and Epidemiology
- Immunotherapy and Immune Responses
- Hepatitis B Virus Studies
- Marriage and Sexual Relationships
- Viral Infections and Outbreaks Research
- Parvovirus B19 Infection Studies
- Social Sciences and Governance
University Medical Center Freiburg
2016-2025
University of Freiburg
2016-2025
Harvard University
2004-2024
Massachusetts General Hospital
2009-2024
University of Oxford
2018-2024
Endometriosis
2021-2024
John Radcliffe Hospital
2021-2024
Philipps University of Marburg
2021-2023
University College London
2017-2023
Oxford University Hospitals NHS Trust
2021-2023
<h3>Context</h3>New trial data and drug regimens that have become available in the last 2 years warrant an update to guidelines for antiretroviral therapy (ART) human immunodeficiency virus (HIV)–infected adults resource-rich settings.<h3>Objective</h3>To provide current recommendations treatment of adult HIV infection with ART use laboratory-monitoring tools. Guidelines include when start what drugs, monitoring response toxic effects, special considerations therapy, managing...
We conducted a double-blind, placebo-controlled trial of oral azidothymidine (AZT) in 282 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. Although significant clinical benefit was documented (N Engl J Med 1987; 317:185–91), serious adverse reactions, particularly bone marrow suppression, were observed. Nausea, myalgia, insomnia, and severe headaches reported more frequently by recipients AZT; macrocytosis developed within weeks most AZT group. Anemia...
Original Article from The New England Journal of Medicine — Isolation HTLV-III Cerebrospinal Fluid and Neural Tissues Patients with Neurologic Syndromes Related to the Acquired Immunodeficiency Syndrome
This double-blind study evaluated treatment with either a single nucleoside or two nucleosides in adults infected human immunodeficiency virus type 1 (HIV-1) whose CD4 cell counts were from 200 to 500 per cubic millimeter.
Guidelines for antiretroviral therapy are important clinicians worldwide given the complexity of field and varied clinical situations in which these agents used. The International AIDS Society-USA panel has updated its recommendations as warranted by new developments field.To provide physicians other human immunodeficiency virus (HIV) with current use HIV-infected adults circumstances there is relatively unrestricted access to drugs monitoring tools. centered on 4 key issues: when start...
<h3>Context</h3>The availability of new antiretroviral drugs and formulations, including in classes, recent data on treatment choices for antiretroviral-naive -experienced patients warrant an update the International AIDS Society–USA guidelines use therapy adult human immunodeficiency virus (HIV) infection.<h3>Objectives</h3>To summarize field to provide current recommendations management laboratory monitoring HIV infection. This report provides key areas management: when initiate therapy,...
We randomly assigned 208 patients who underwent brain biopsy for presumptive herpes simplex encephalitis to receive either vidarabine (15 mg per kilogram of body weight day) or acyclovir (30 10 days. Sixty-nine (33 percent) had biopsy-proved disease; 37 received vidarabine, and 32 acyclovir. The mortality in the recipients was 54 percent, as compared with 28 percent (P = 0.008). Six-month varied according Glasgow coma score at onset therapy. For scores >10, 7 10, ≤6, 42, 46, 67 treated 0,...
Assays for drug resistance testing in human immunodeficiency virus type 1 (HIV-1) infection are now available and clinical studies suggest that viral is correlated with poor virologic response to new therapy. The International AIDS Society-USA sought update prior recommendations provide guidance clinicians regarding indications HIV-1 testing.An 13-member physician panel expertise basic science, research, patient care involving HIV antiretroviral drugs was reconvened the use of testing.The...
Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred last 2 years, prompting revision guidelines for antiretroviral management adults with established HIV infection.To update recommendations physicians who provide care regarding when to start therapy, what drugs with, change drug regimens, and regimens switch after therapy fails.Evidence was identified reviewed by a 16-member noncompensated panel expertise HIV-related basic science clinical research,...
To provide current recommendations for antiretroviral therapy human immunodeficiency virus (HIV) disease. The original International AIDS Society-USA 13-member panel representing international expertise in research and care of patients with HIV infection. following were considered: Newly available clinical basic science study results, including phase 3 controlled trials; clinical, virological, immunologic end-point data; interim analyses studies presented at national conferences;...
<h3>Context</h3>Recent data regarding the consequences of untreated human immunodeficiency virus (HIV) infection and expansion treatment choices for antiretroviral-naive antiretroviral-experienced patients warrant an update International AIDS Society–USA guidelines use antiretroviral therapy in adults with HIV infection.<h3>Objectives</h3>To provide updated recommendations management HIV-infected adults, using drugs laboratory monitoring tools available international, developed-world...
Normal blood-derived monocyte/macrophages were found to be susceptible infection in vitro by human T lymphotropic virus type III (HTLV-III), the etiologic agent of acquired immunodeficiency syndrome. In addition, HTLV-III was recovered from patients infected with this virus. The above findings raise possibility that HTLV-III-infected may serve as a vehicle for dissemination target organs and reservoir viral persistence, has been shown other lentiviruses including visna caprine arthritis encephalitis
New information about the benefits and limitations of testing for resistance to human immunodeficiency virus (HIV) type 1 (HIV-1) drugs has emerged. The International AIDS Society-USA convened a panel physicians scientists with expertise in antiretroviral drug management, HIV-1 resistance, patient care provide updated recommendations testing. Published data presentations at scientific conferences, as well strength evidence, were considered. Properly used can improve virological outcome among...
We studied measures of human immunodeficiency virus (HIV) replication, the viral phenotype, and immune function (CD4 cell counts) relation changes in these indicators to clinical outcomes a subgroup patients controlled trial early antiretroviral treatment for HIV, AIDS Clinical Trials Group Study 175.
Abstract Human T‐cell lymphotropic virus type III (HTLV‐III) has been isolated from neural tissues and cerebrospinal fluid (CSF) of patients with neurological syndromes associated the acquired immune deficiency syndrome (AIDS) may be directly involved in pathogenesis syndromes. To detect HTLV‐III antigen AIDS, immunoperoxidase studies using a goat anti‐HTLV‐III serum were performed on frozen tissue sections brain, spinal cord, nerve 13 AIDS or HTLV‐III–related was cultured CSF 11 these...
Human T-lymphotropic virus type III (HTLV-III) is the probable etiologic agent for acquired immune deficiency syndrome (AIDS). HTLV-III was isolated from semen and blood of a healthy homosexual man whose serum contains antibodies to HTLV-III. The finding in supports epidemiologic data that suggest AIDS can be transmitted sexually. In addition, demonstration individual establishes an asymptomatic, virus-positive carrier state which may important dissemination and, consequently, AIDS.
Original Article from The New England Journal of Medicine — Controlled Clinical Trial Prophylactic Human-Leukocyte Interferon in Renal Transplantation Effects on Cytomegalovirus and Herpes Simplex Virus Infections